Emer­gent gets a chance to re­deem it­self in mR­NA vac­cine deal with Prov­i­dence Ther­a­peu­tics

One of the most no­to­ri­ous names in Amer­i­can drug man­u­fac­tur­ing has land­ed a con­tract with a Cana­di­an drug­mak­er look­ing to make waves in the mR­NA Covid-19 vac­cine game and fill in the gaps the two big mR­NA com­pa­nies have strug­gled to fill.

In a five-year deal worth about $90 mil­lion, Emer­gent BioSo­lu­tions agreed to pro­vide CD­MO ser­vices to Prov­i­dence Ther­a­peu­tics, in­clud­ing drug de­vel­op­ment, bulk drug sub­stance for­mu­la­tion and fi­nal prod­uct man­u­fac­tur­ing to help the drug’s de­vel­op­ment. Pro­duc­tion is set to com­mence in 2022, if all goes ac­cord­ing to plan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER